RenovoRx (RNXT) EBITDA Margin (2025 - 2026)
RenovoRx (RNXT) posted EBITDA Margin of 616.16% for Q1 2026, up 58.36% sequentially from 1479.83% in Q4 2025, and up 96252.0% YoY from N/an in Q1 2025.
RenovoRx (RNXT) EBITDA Margin (2025 - 2026) Analysis & Trends
RenovoRx has reported EBITDA Margin for 2 years, with the latest figure at 616.16% in Q1 2026.
- Quarterly EBITDA Margin rose 96252.0% year-over-year to 616.16% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 864.27% (changed N/A YoY) and the FY2025 annual result came in at 1113.98%, up 2439765.0% from the prior year.
- EBITDA Margin grew to 616.16% in Q1 2026 per RNXT's latest filing, from 1479.83% in the prior quarter.
- Over five years, EBITDA Margin peaked at 616.16% in Q1 2026 and troughed at 1578.68% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.75% |
| 10 | RenovoRx | 59.83 Mn | 59.83 Mn | 766,000.00 | -368.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -368.43% |
| Mar 31, 2026 | -616.16% |
| Dec 31, 2025 | -1,479.83% |
| Sep 30, 2025 | -1,203.01% |
| Jun 30, 2025 | -634.60% |
| Mar 31, 2025 | -1,578.68% |